View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 26, 2018

Researchers devise new approach to target Alzheimer’s

An international research team has developed a new method that addresses the cause of Alzheimer’s disease by targeting toxic particles responsible for death of healthy brain cells.

An international research team has developed a new method that addresses the cause of Alzheimer’s disease by targeting toxic particles responsible for death of healthy brain cells.

The team, which comprises of researchers from the University of Cambridge in the UK and Sweden’s Lund University , expects the new approach to help in the development of new dementia medications.

During the research, the team identified abnormal deposits called protein oligomers as the most likely reason for the development of dementia.

The proteins normally participate in cell processes. However, in Alzheimer’s patients, they were found to become faulty, cause the formation of clumps and destroy healthy nerve cells.

University of Cambridge Chemistry department professor Michele Vendruscolo said: “This is the first time that a systematic method to go after the pathogens – the cause of Alzheimer’s disease – has been proposed.

“As the pathogens have now been identified as small clumps of proteins known as oligomers, we have been able to develop a strategy to aim drugs at these toxic particles.”

“As the pathogens have now been identified as small clumps of proteins known as oligomers, we have been able to develop a strategy to aim drugs at these toxic particles.”

The researchers believe that the new approach will facilitate systematic development of compounds to target these toxic protein oligomers.

Vendruscolo added: “Our research is based on the major conceptual step of identifying protein oligomers as the pathogens and reports a method to systematically develop compounds to target them. This approach enables a new drug discovery strategy.”

The team estimates that the first drug candidates based on their new approach will enter clinical trials in about two years.

Furthermore, the researchers have co-founded a biotechnology company called Wren Therapeutics, which will focus on advancing the ideas developed at Cambridge into new techniques to diagnose and treat misfolding disorders, including Alzheimer’s.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology